1. Home
  2. MGTX vs BIOA Comparison

MGTX vs BIOA Comparison

Compare MGTX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

N/A

Current Price

$11.77

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo BioAge Labs Inc.

BIOA

BioAge Labs Inc.

N/A

Current Price

$20.69

Market Cap

967.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MGTX
BIOA
Founded
2015
2015
Country
United States
United States
Employees
N/A
62
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
967.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
MGTX
BIOA
Price
$11.77
$20.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$24.57
$51.50
AVG Volume (30 Days)
817.3K
555.7K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
33.02
N/A
EPS
N/A
N/A
Revenue
$81,391,000.00
N/A
Revenue This Year
$141.38
$720.93
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
144.57
N/A
52 Week Low
$6.62
$4.11
52 Week High
$15.35
$25.96

Technical Indicators

Market Signals
Indicator
MGTX
BIOA
Relative Strength Index (RSI) 51.57 43.77
Support Level $8.84 $18.53
Resistance Level $15.35 $21.29
Average True Range (ATR) 0.67 1.47
MACD -0.20 -0.47
Stochastic Oscillator 20.85 8.15

Price Performance

Historical Comparison
MGTX
BIOA

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

About BIOA BioAge Labs Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Share on Social Networks: